NEUROCOGNITIVE DISORDERS
Clinical trials for NEUROCOGNITIVE DISORDERS explained in plain language.
Never miss a new study
Get alerted when new NEUROCOGNITIVE DISORDERS trials appear
Sign up with your email to follow new studies for NEUROCOGNITIVE DISORDERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New dosing strategy aims to make Alzheimer's drug safer and more effective
Disease control OngoingThis study tests different dosing schedules of the drug donanemab in about 1,175 people with early symptomatic Alzheimer's disease. The goal is to find a regimen that lowers brain amyloid plaques while reducing the risk of a side effect called ARIA-E (brain swelling or small blee…
Matched conditions: NEUROCOGNITIVE DISORDERS
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a new drug slow Alzheimer's? large trial underway
Disease control OngoingThis phase 3 study tests whether donanemab, an antibody given through an IV, can safely slow cognitive decline in 1500 people with early Alzheimer's. Participants receive either the drug or a placebo for up to 93 weeks. The main goal is to measure changes in thinking and daily fu…
Matched conditions: NEUROCOGNITIVE DISORDERS
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Zapping the brain to boost motivation in seniors
Symptom relief OngoingThis study tests whether a gentle electrical brain stimulation technique called tDCS, combined with cognitive training on a tablet, can reduce apathy in older adults with mild cognitive impairment. Apathy is a lack of motivation and interest that can affect daily life. The trial …
Matched conditions: NEUROCOGNITIVE DISORDERS
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC